A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Phase 1
60
about 6.9 years
18–60
1 site in MO
About this study
This trial is testing a treatment called P-CD19CD20-ALLO1 for people with multiple sclerosis. The goal is to see how safe and well the treatment works, including how it affects cells in the body and its effects on the disease.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive P-CD19CD20-ALLO1 Cells
- 2.Take Cyclophosphamide
- 3.Take Fludarabine
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine
infusion
Primary: Number of Participants With Adverse Events (AEs), Number of Participants With Dose-limiting Toxicity (DLTs) at Each Dose Level of P-CD19CD20-ALLO1
Neurology